Small: The Endosomal Traffic Jam

Benjamin Aaron Gustafsson AdultCognitiveDisease.com

---

The Endosomal Traffic Jam: Evaluating the Retromer

Hypothesis in Alzheimer's Disease Pathogenesis

Abstract

For decades, the amyloid cascade hypothesis has dominated Alzheimer's disease (AD) research, positing that extracellular amyloid-beta accumulation initiates neurodegeneration. The modest clinical efficacy and adverse event profiles of recent anti-amyloid immunotherapies suggest a fundamental theoretical limitation. This analysis examines the retromer hypothesis proposed by Scott A. Small and colleagues, which positions endosomal traffic dysfunction as an upstream pathogenic driver in AD. By tracing the historical record from Oskar Fischer's early observations through modern genomic validation, this paper assesses whether endosomal dysfunction represents a primary mechanism, explores the selective vulnerability of the lateral entorhinal cortex through functional imaging and cell biology, and evaluates the translational potential of retromer-enhancing therapies including AAV9-SORL1 and RhoGEF12 inhibition. The hypothesis offers a plausible mechanism that accounts for several major observations in AD but remains incomplete regarding the temporal relationship between endosomal dysfunction and amyloid production, the role of non-neuronal compartments, and the clinical applicability of proposed interventions.

Introduction: The Clinical Impasse in Alzheimer's Therapeutics

The contemporary landscape of AD research is marked by a significant gap between biomarker advances and clinical translation. As of early 2025, 182 active clinical trials assess 138 novel therapeutic agents across over 50,000 participants. Anti-amyloid monoclonal antibodies (lecanemab, donanemab) have demonstrated that amyloid clearance is pharmacologically achievable. However, clinical outcomes show modest cognitive stabilization, significant risks including amyloid-related imaging abnormalities (microhemorrhages, edema), and deployment challenges in non-academic settings with mixed etiologies. This clinical plateau raises a core question: while amyloidosis is a definitive histological hallmark, does targeting extracellular plaques intervene too late or miss upstream drivers of neuronal toxicity⁸? One persistent paradox merits attention: the medial temporal lobe experiences the earliest and most severe neurodegeneration despite often displaying the lowest extracellular amyloid plaque burden. Within this theoretical impasse, Scott A. Small proposes that endosomal trafficking dysfunction—specifically failures in retromer-mediated cargo recycling—represents a primary, upstream pathogenic mechanism. The hypothesis posits that when the retromer complex fails to recycle cargo proteins from the early endosome, accumulation of amyloid precursor protein (APP), BACE1, and synaptic receptors within the endosomal lumen triggers amyloidogenic processing, early synaptic failure, and tau secretion. This analysis evaluates the validity, historical precedent, and therapeutic potential of this hypothesis while identifying its limitations and unresolved questions.

Literature Review: Historical Context and Paradigm Precedents

The Prague and Munich Schools: Fischer and Alzheimer

The clinical and pathological definitions of AD emerged from early 20th-century academic rivalries. Alois Alzheimer (1906) documented extracellular plaques and intracellular tangles in Auguste D., a 51-year-old with presenile dementia. Alzheimer himself remained uncertain whether this represented a distinct disease rather than early-onset senile dementia. Concurrently, Oskar Fischer (1907) documented identical neuritic plaques in twelve cases of senile dementia, establishing a more comprehensive clinicopathological correlation¹⁹. However, Emil Kraepelin's Munich school rapidly codified the presenile form as "Alzheimer's disease" in his 1910 textbook, effectively eclipsing Fischer's work on senile variants. Fischer's contributions were further obscured by geopolitical circumstances; as a Jewish scholar, he lost academic positions and died in the Theresienstadt concentration camp in 1942. His theoretical work, however, showed prescient thinking. Unlike Alzheimer's descriptive approach, Fischer pursued etiology, hypothesizing that plaques resulted from active biological processes (though his specific pathogen theories proved incorrect). His conceptualization of plaques as active, reactive manifestations rather than passive debris loosely prefigures modern neuroimmunological interpretations, which increasingly view amyloid as a downstream antimicrobial response or stress marker rather than a root cause.

Ultrastructural Observations: From Secondary Phenotype to Primary Mechanism

The molecular biology revolution of the 1980s-1990s, highlighted by sequencing of the Aβ peptide and discovery of APP and Presenilin mutations, consolidated the amyloid cascade framework as dominant. Amyloidosis and tau pathology became the field's focus. During this period, Ralph Nixon and Anne Cataldo conducted parallel ultrastructural work using immunoelectron microscopy, observing robust enlargement of endosomal and lysosomal compartments in postmortem AD brains²². They documented up to eightfold increases in hydrolase-positive vacuolar compartments in vulnerable regions compared to age-matched controls. Crucially, these abnormalities preceded significant amyloid deposition in sporadic AD and early-stage Down syndrome (which invariably develops AD pathology due to APP triplication). Despite these empirical observations, the field interpreted endosomal enlargement as a secondary phenomenon—the cell's reactive attempt to clear overwhelming extracellular amyloid. Only with the genomic era and methodological innovations by researchers like Small was this interpretation revised: the enlarged endosome reframed not as symptom but as potential root cause.

Historiographical Summary

Era | Key Figures | Focus | Outcome 1906–1910 | Alzheimer, Fischer, Kraepelin | Plaques and tangles as disease hallmarks | Political codification narrowed theoretical scope 1980s–1990s | Glenner, Hardy, Selkoe | Biochemical characterization of Aβ; amyloid cascade hypothesis | Consolidation of extracellular pathology as primary 1990–2000 | Nixon, Cataldo | Ultrastructural endolysosomal enlargement | Interpreted as secondary response; largely overlooked 2005–Present | Small, Petsko, Kim | Retromer deficiency via model-guided microarray; endosomal traffic jam as upstream hub | Emerging alternative framework; limited clinical translation

Analytical Framework: Model-Guided Transcriptomics

The identification of retromer as a critical vulnerability did not emerge from standard genome-wide association studies (GWAS). Rather, it resulted from a methodologically novel approach termed "model-guided microarray" analysis, pioneered by Small, Tae-Wan Kim, and colleagues.

Addressing Signal-to-Noise in Transcriptomics

Microarray analysis of late-stage postmortem AD brains yields thousands of differentially expressed genes, most reflecting terminal cell death, inflammation, and physiological collapse rather than primary drivers. Small's group developed a rigorous analytical filter based on documented anatomical disease spread. High-resolution fMRI studies had established that the entorhinal cortex (EC) experiences profound early dysfunction, while the adjacent dentate gyrus (DG) remains relatively preserved initially. By comparing tissue from the vulnerable EC to the resilient DG across a broad age span, researchers established an a priori spatiotemporal model²⁴: any gene fundamentally driving pathogenesis must be differentially regulated in the EC before regulation in the DG. Out of tens of thousands of transcripts, five molecules survived this filter. The molecule best conforming to the early disease profile was VPS35, the core component of the retromer complex. Subsequent western blotting confirmed that VPS35 and VPS26 were significantly downregulated in brain regions selectively vulnerable to AD. In vitro studies using small interfering RNAs confirmed that experimental VPS35 reduction regulates Aβ peptide levels, establishing a functional link between retromer deficiency and amyloidogenic processing.

What This Framework Cannot Determine: This spatiotemporal approach is powerful for regional

prioritization but cannot definitively establish causation in living humans. The correlation between VPS35 downregulation and disease vulnerability requires temporal validation—demonstration that VPS35 loss precedes neuronal dysfunction in longitudinal cohorts.

Main Analysis: The Endosomal Traffic Jam Hypothesis

The hypothesis proposes that early endosomal dysfunction creates a pathogenic bottleneck affecting intracellular cargo recycling. Four classes of AD-associated genes show functional relationships to endosomal integrity, though the mechanistic specificity varies.

Four Gene Classes and Endosomal Convergence

1. Endosomal Trafficking Genes (Direct Effect) SORL1, BIN1, PICALM, and CD2AP directly govern membrane trafficking. SORL1 (sortilin-related receptor
2. has emerged as a potent genetic risk factor, with rare causal mutations conferring risks equivalent to autosomal-dominant mutations in APP or PSEN1. SORL1 acts as a physical bridge, tethering cargo to the VPS35-retromer complex for retrograde transport³⁷. When SORL1 or retromer components are deficient, cargo accumulates within the endosome, initiating the "traffic jam."
3. APP Processing Genes (Secondary Effect) APP, PSEN1, and PSEN2 mutations are classical early-onset familial AD drivers. Amyloidogenic cleavage of APP by BACE1 occurs predominantly in the acidic endosomal lumen. When an endosomal traffic jam occurs, the residency time of both APP and BACE1 within the endosome increases, favoring pathological cleavage into toxic Aβ and C-terminal fragments (CTF). Intracellular accumulation of these fragments alters endosomal membrane permeability, potentially worsening the traffic jam. However, the temporal primacy of this effect remains contested.
4. Cholesterol Metabolism (APOE4) (Indirect Effect) APOE4 remains the strongest single genetic risk factor for late-onset AD. Beyond inhibiting extracellular amyloid clearance, APOE4 has been shown to interfere with endosomal recycling. It alters neuronal and glial lipid dynamics, leading to accumulation of damaging lipid droplets in microglia and trapping surface receptors in the endolysosomal network, independent of amyloid presence. The specificity of this mechanism remains incompletely characterized.
5. Immune Response (TREM2) (Indirect Effect) Microglial phagocytic receptors rely on the retromer complex for transport to the cell surface. Endosomal dysfunction impairs their recycling, blunting microglial phagocytic clearance. This effect is mechanistically distinct from neuronal endosomal dysfunction and represents a separate, parallel pathway. Critical Limitation: The convergence of these gene classes on endosomal dysfunction is partly thematic. Endosomal trafficking genes show direct, mechanistic effects. APP processing genes show conditional secondary effects dependent on prior endosomal dysfunction. APOE4 and TREM2 effects are more indirect and partially independent of endosomal dynamics. Labeling all four as equally "converging" on a single hub obscures these mechanistic differences.

Downstream Pathophysiology: Synaptic Failure and Tau Secretion

The hypothesis's explanatory power lies in connecting two previously disconnected AD features.

Glutamate Receptor Depletion: Synaptic plasticity requires constant recycling of AMPA and NMDA

receptors from the early endosome to the postsynaptic membrane. Retromer deficiency traps these receptors in the endosomal lumen, shunting them toward lysosomal degradation. This aligns with observed synaptic depression, diminished long-term potentiation, and dendritic spine loss occurring years before neuronal cell death. Exosomal Tau Secretion: Small's laboratory demonstrated a structural link between endosomal dysfunction and tau secretion. As endosomal trafficking stalls, the compartment progressively matures into a multivesicular body (MVB). Cargo trapped on the limiting membrane (such as CTF) and cytosolic proteins incidentally present in the lumen (such as tau) are packaged into intraluminal vesicles (ILVs). When the congested MVB fuses with the plasma membrane, these ILVs are released as exosomes, facilitating trans-synaptic tau spread. Recent high-throughput mass spectrometry of cerebrospinal fluid in VPS35-knockout mice identified specific biomarkers of endosomal failure, including elevation of APLP1 amino terminus, CHL1, and mid-domain tau. These markers show correlation with disease progression in human cohorts¹³, though causality and predictive value remain to be established in prospective studies.

Anatomy of Selective Vulnerability: The Lateral Entorhinal Cortex

One core mystery in neurodegeneration is anatomical selectivity: why do specific regions succumb decades before others? AD follows a stereotyped spatial progression, not uniform diffusion.

High-Resolution Circuit Mapping

High-resolution fMRI optimized for sub-millimeter detection of hippocampal changes revealed the earliest detectable metabolic dysfunction exclusively in the transentorhinal and lateral entorhinal cortex (LEC)¹⁵. The LEC integrates non-spatial memory, object recognition, and olfactory information into the broader hippocampal formation⁴⁷. In transgenic models expressing early AD pathology (EC-App/Tau), in vivo electrophysiology shows that LEC neurons become persistently hyperactive but with exceptionally low information content. Specifically, "object cells" and "trace cells" responsible for coding object presence lose firing fidelity, manifesting as episodic memory loss, spatial disorientation, and item misplacement.

Cell Biology and Network Topology

Layer II entorhinal neurons possess massive morphological complexity, with total dendritic lengths approaching 18 millimeters. Maintaining synaptic plasticity across this vast surface area requires disproportionate reliance on rapid, high-volume endosomal recycling⁴⁸. Recent investigations demonstrate that the transentorhinal cortex relies on a distinct biochemical architecture. Neurons are enriched with a specific retromer sub-complex organized around VPS26b (versus the ubiquitous VPS26a). This VPS26b-retromer core is differentially dedicated to rapid glutamate receptor recycling. When VPS26b is experimentally depleted in mice, immediate, severe deficits in entorhinal neurotransmission and memory function result, phenocopying early human AD in this specific circuit. Subsequent autopsy data confirmed that VPS26b expression is severely deficient in the transentorhinal cortex of human AD patients. Macro-scale network analyses demonstrate that regions anatomically connected to this vulnerable LEC hub preferentially propagate pathology through network transmission along axonal wiring pathways⁴⁶. What This Analysis Cannot Determine: While the morphological and genetic architecture of the LEC provides plausible explanation for regional vulnerability, this does not establish that endosomal dysfunction is the sole or primary driver of LEC degeneration. Other factors—vascular insufficiency, network topology effects, or cell-type-specific protein expression—may contribute independently or synergistically.

Translational Horizons: Retromer Restoration Strategies

If the amyloid cascade hypothesis aims to "clean up the flood" in the extracellular space⁹ via antibodies, the endosomal hypothesis aims to "unclog the drain" intracellularly. Multiple modalities for retromer stabilization have advanced from theory to development.

Pharmacological Chaperones

Initial drug discovery focused on small molecule chaperones designed to stabilize the retromer complex, preventing degradation and boosting functional half-life at the endosomal membrane. Compounds such as R33, R55, and TPT-260 demonstrated proof-of-concept efficacy in human induced pluripotent stem cell (hiPSC) models, increasing SORL1 and APP trafficking out of the early endosome and reducing tau phosphorylation independent of total amyloid levels. However, modest potency, low half-life, and off-target specificity indicate these early-generation compounds are better suited as in vitro tools rather than viable human drugs. Development has shifted toward more targeted interventions.

AAV9-SORL1 Gene Therapy

SORL1 loss-of-function variants occur in a significant subset of AD patients, making gene replacement a logical approach. A major technical barrier exists: full-length human SORL1 exceeds the packaging capacity of standard AAV capsids. Researchers engineered a truncated "SORL1 mini-gene" construct, preserving essential 3FN dimerization and retromer-binding domains while eliminating non-essential sequences¹⁷. Packaged into AAV9 (effective at crossing the blood-brain barrier), this therapy (AAV9-SORL1) is advancing through preclinical development⁵⁸. In vitro studies confirm that the AAV9-delivered mini-receptor localizes to endosomal puncta, co-localizes with endogenous retromer, and significantly boosts recycling capacity. In vivo stereotaxic infusions in wild-type mice and SORL1-haploinsufficient Göttingen minipigs demonstrated robust, dose-dependent transduction⁶⁰. However, substantial caution is warranted regarding viral therapies for multiprotein complexes. Supraphysiological overexpression of single complex subunits—as seen in SOD1 models of amyotrophic lateral sclerosis—can create stoichiometric imbalances and paradoxical toxicity. Successful translation requires highly calibrated, cell-type-specific promoter regulation to enhance rather than disrupt endogenous machinery. What This Approach Cannot Determine: Clinical efficacy in humans remains unestablished. Preclinical models may not predict response in the complex, aged human brain with multiple concurrent pathologies. Optimal dosing, timing of intervention, and patient-selection criteria are unknown.

RhoGEF12 and ROCK2 Kinase Inhibition (2026)

As of March 2026, Small's laboratory unveiled a novel regulatory mechanism governing SORL1-retromer interaction. The retromer complex's efficiency is regulated by phosphorylation state of SORL1's cytoplasmic tail. ROCK2 (Rho-associated kinase 2) phosphorylates this domain, reducing SORL1's binding affinity for retromer and halting cargo recycling. ROCK2 is activated upstream by RhoGEF12 (Rho guanine nucleotide exchange factor 12), which is significantly upregulated in Alzheimer's disease brains⁵⁷. A specific pharmacological inhibitor of RhoGEF12 (Y1634) reduced ROCK2-mediated phosphorylation, enhancing SORL1-retromer binding. When applied to primary mouse neurons and human iPSC-derived neurons with AD-associated mutations, the RhoGEF12 inhibitor increased endosomal SORL1-retromer recycling and reduced both Aβ and CTF secretion in a dose-dependent manner. This discovery identifies a non-viral pathway to enhance endosomal recycling using specific kinase-pathway inhibitors, circumventing AAV-related risks.

What This Approach Cannot Determine: These studies have been conducted in cellular systems and

require validation in whole-organism models, particularly regarding efficacy in aging brains, target engagement in the central nervous system, and off-target effects of RhoGEF12 inhibition on other cell types and physiological processes.

Critical Evaluation: Competing Hypotheses and Unresolved Questions

The Temporal Primacy Problem

Proponents of the amyloid hypothesis concede that endosomal traffic jams occur in AD but debate their position in the pathogenic timeline⁶³. The "amyloid-first" camp argues that retromer dysfunction may not be the primary etiological spark but rather a catastrophic secondary effect of overwhelming extracellular oligomerization⁴³. They note that autosomal-dominant APP and presenilin mutations—which directly and specifically alter Aβ production—guarantee early-onset disease, suggesting intracellular amyloid toxicity damages the endosomal membrane⁶⁵. Small's model counters by pointing to LOAD genetics: endosomal mutations (like SORL1) act as primary upstream drivers independently of defects in APP processing. However, fully separating this intertwined feedback loop—where primary endosomal jams cause amyloid production, and primary amyloid accumulation worsens endosomal jams—remains technically challenging in human in vivo cohorts. This remains the most significant unresolved question in the field. Researchers including Pimplikar and Arnsten have noted that early intracellular tau pathology itself can precipitate endosomal blockades, adding another layer of complexity to determining which proteinopathy initiates the cycle.

The Cellular Heterogeneity Problem

A substantial critique suggests that neuronal endosomal trafficking represents only part of the biological equation. As the field increasingly emphasizes neuroinflammation, microglial retromer function has come under investigation. Microglia uniquely rely on retromer to recycle vital phagocytic receptors (such as TREM2) to their cell surface. Small's earlier models are primarily neuronal-centric. Reconciling how astrocytic and microglial endolysosomal failures contribute simultaneously to disease remains incomplete. Recent findings regarding APOE4's role in generating damaging lipid droplets specifically within microglia further complicate the landscape³⁹. This suggests that effective endosomal therapeutics must achieve efficacy across multiple distinct cell types—addressing neuronal tau secretion and microglial phagocytic failure simultaneously—a substantially more complex challenge than currently modeled.

Alternative Frameworks

The endosomal hypothesis does not exclude other primary mechanisms. Tau-first models propose that early intracellular tau accumulation initiates the cascade. Multi-hit models suggest that no single lesion suffices; rather, combinations of amyloid, tau, endosomal dysfunction, and metabolic failure drive disease. The endosomal hypothesis may be one necessary but insufficient factor in a more complex causal architecture.

Clinical and Economic Barriers

Translation from cellular theory to standard care faces substantial inertia. The monumental financial investments in anti-amyloid therapies have structurally biased clinical trial infrastructure, biomarker development, and regulatory frameworks toward amyloid endpoints. Demonstrating clinical efficacy of endosomal therapeutics requires validation of novel fluid biomarkers (CSF APLP1, mid-domain tau) and costly proof-of-concept trials in preclinical, asymptomatic populations before catastrophic neuronal loss occurs. These trials remain unfunded and unplanned as of 2026.

What This Analysis Cannot Determine

1. Temporal Causality in Humans: Whether endosomal dysfunction initiates the pathogenic cascade or occurs as a secondary response to amyloid accumulation cannot be definitively established from current evidence. Longitudinal neuroimaging combined with fluid biomarkers of endosomal function in presymptomatic populations would be required, but such studies are not yet designed or funded.
2. Sufficiency of Retromer Restoration: Whether enhancing retromer function alone is sufficient to prevent or reverse disease progression remains unknown. The hypothesis implicitly assumes that if endosomal dysfunction is the primary driver, then its correction should arrest disease. This assumption has not been tested in living organisms.
3. Cell-Type and Regional Specificity: The relative contributions of neuronal versus glial endosomal dysfunction to overall disease progression remain unclear. The framework does not adequately address whether therapeutic interventions must target all vulnerable cell types or whether neuronal correction alone suffices.
4. Generalizability Across AD Subtypes: The hypothesis was developed primarily in the context of sporadic AD and familial AD with APP/PSEN mutations. Its applicability to atypical variants (posterior cortical atrophy, logopenic aphasia) or AD-resistant phenotypes remains untested.
5. Clinical Efficacy and Optimal Intervention Timing: No human clinical trials of retromer-enhancing therapies have been completed or published. The optimal stage for intervention (preclinical, prodromal, mild cognitive impairment), patient selection criteria, and expected cognitive outcomes remain speculative.
6. Integration with Non-Neuronal Pathology: The mechanisms by which endosomal dysfunction in astrocytes, oligodendrocytes, and endothelial cells contribute to disease are poorly characterized. Vascular dysfunction and blood-brain barrier disruption, both present in AD, may be independent or synergistic factors not explained by the endosomal hypothesis.
7. Off-Target Effects of Proposed Therapeutics: RhoGEF12 inhibitors and AAV9-based gene delivery have not been evaluated for their effects on non-target tissues or long-term safety in chronically treated populations. The stoichiometric consequences of SORL1 overexpression in aging neurons require more comprehensive investigation.

Synthesis

The endosomal traffic jam hypothesis offers a coherent mechanistic framework that accounts for several major observations in Alzheimer's disease: the selective anatomical vulnerability of the medial temporal lobe, early synaptic failure preceding neuronal cell death, the trans-synaptic spread of tau pathology, and the convergence of multiple genetic risk factors onto intracellular trafficking pathways. Historically, the hypothesis represents a significant shift from extracellular pathology as primary to intracellular dysfunction as upstream cause. The work of Small and colleagues has rigorously advanced this framework through novel analytical methods, functional imaging, cellular biology, and early-stage drug discovery. However, the hypothesis remains incomplete. The temporal relationship between endosomal dysfunction and amyloid production is fundamentally uncertain—whether endosomal jams cause amyloid accumulation or vice versa cannot be definitively separated in current experimental systems. The framework is primarily neuronal-centric and inadequately addresses glial contributions. The clinical translation of proposed therapies faces substantial barriers of proof-of-concept design, regulatory pathway uncertainty, and lack of validated biomarkers for patient selection. The most promising near-term path forward involves prospective, longitudinal studies combining high-resolution functional imaging with novel fluid biomarkers of endosomal function in large, well-characterized preclinical populations. These studies could establish the temporal sequence of endosomal dysfunction, amyloid accumulation, and cognitive decline, answering the central causal question. Parallel mechanistic studies in human tissue, particularly regarding cell-type specificity and regional variation, would clarify whether endosomal therapeutics must be cell-type targeted or broadly applicable. The retromer hypothesis should not replace but rather complement and constrain the amyloid framework, positioning these mechanisms within a more comprehensive, multi-system model of Alzheimer's disease pathogenesis.

The Validity Ledger

The argument above is only as strong as its weakest load-bearing joint, and the reader is owed an explicit accounting of where it stands on the ground and where it stands on inference.

Works Cited

1. Cummings JL, Zhou Y, Lee G, Zhong K, Fonseca J, Leisgang-Osse AM, et al.. Alzheimer's disease drug development pipeline: 2025. Alzheimers Dement (N Y) 2025;11(2):e70098. DOI 10.1002/trc2.70098.

2. New Trials, New Targets: New Hope for Alzheimer's - Medscape, accessed March 23, 2026, https://www.medscape.com/viewarticle/new-trials-new-targets-new-hope-alzhe imers-2025a1000hob

3. Cummings JL, Zhou Y, Lee G, Zhong K, Fonseca J, Leisgang-Osse AM, et al.. Alzheimer's disease drug development pipeline: 2025. Alzheimers Dement (N Y) 2025;11(2):e70098. DOI 10.1002/trc2.70098.

4. Expanding the Alzheimer's Treatment Landscape: A 2026 Forecast - BrightFocus, accessed March 23, 2026, https://www.brightfocus.org/resource/expanding-the-alzheimers-treatment-land scape-a-2026-forecast/

5. Symposia - Texas Alzheimer's Research and Care Consortium, accessed March 23, 2026, https://www.txalzresearch.org/research/symposia/

6. Fin S, Moayedikia A, Wiil UK. Dual-model deep learning for Alzheimer's prognostication. Comput Biol Med 2026;208:111672. DOI 10.1016/j.compbiomed.2026.111672.

7. Wu CY, Chen L, Dickson JR, Zhang B, Arnold SE, Dodge HH. Synthetic control methods for n-of-1 and parallel-group trials in Alzheimer's disease: A proof-of-concept study using the I-CONECT. Alzheimers Dement 2025;21(7):e70460. DOI 10.1002/alz.70460.

8. Targeting Endosomal Trafficking in Alzheimer's Disease - Advances for Medical Professionals | NewYork-Presbyterian, accessed March 23, 2026, https://www.nyp.org/publications/professional-advances/neuro/targeting-endoso mal-trafficking-in-alzheimers-disease

9. Scott-Small nihms902458.pdf

10. Small SA, Simoes-Spassov S, Mayeux R, Petsko GA. Endosomal Traffic Jams Represent a Pathogenic Hub and Therapeutic Target in Alzheimer's Disease. Trends Neurosci 2017;40(10):592-602.2017.08.003.

    Find this paper

11. Small SA, Petsko GA. Retromer in Alzheimer disease, Parkinson disease and other neurological disorders. Nat Rev Neurosci 2015;16(3):126-32. DOI 10.1038/nrn3896.

12. Pérez-Torres EJ, Utkina-Sosunova I, Mishra V, Barbuti P, De Planell-Saguer M, Dermentzaki G, et al.. Retromer dysfunction in amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences 2022;119(26). DOI 10.1073/pnas.2118755119.

13. Neuron-Specific Retromer Identified—Does It Stave Off Alzheimer's? | ALZFORUM, accessed March 23, 2026, https://www.alzforum.org/news/research-news/neuron-specific-retromer-identifi ed-does-it-stave-alzheimers

14. Central Trafficking Compartment in Neurons Malfunctions in a Majority of Alzheimer's Patients | Columbia University Irving Medical Center, accessed March 23, 2026, https://www.cuimc.columbia.edu/news/central-trafficking-compartment-neurons -malfunctions-majority-alzheimers-patients 15. fMRI and Mouse Models of Alzheimer's Disease - Scott Small - Grantome, accessed March 23, 2026, https://www.ncbi.ncbi.grantome.com/grant/NIH/R01-AG025161-09

15. Taub Institute: News - Columbia Neurology Research, accessed March 23, 2026, https://columbianeuroresearch.org/taub/news-taub.html 17. (PDF) AAV9ISORL1 gene therapy for Alzheimer's disease - ResearchGate, accessed March 23, 2026, https://www.researchgate.net/publication/387856334_AAV9-SORL1_gene_therap y_for_Alzheimer's_disease

16. RhoGEF12 regulates endosomal SORL1-retromer and its inhibition is therapeutic in human neuronal models of Alzheimer's disease | bioRxiv, accessed March 23, 2026, DOI 10.64898/2026.03.06.709427">https://www.biorxiv.org/content/10.64898/2026.03.06.709427

17. Alzheimer's Disease Research: What Has Guided Research So Far and Why It Is High Time for a Paradigm Shift 3031315693, 9783031315695 - DOKUMEN.PUB, accessed March 23, 2026, https://dokumen.pub/alzheimers-disease-research-what-has-guided-research-s o-far-and-why-it-is-high-time-for-a-paradigm-shift-3031315693-9783031315695.html

18. American Histories - The Pennsylvania Gazette, accessed March 23, 2026, https://thepenngazette.com/pdfs/PennGaz0321_issue.pdf

19. Are the Infectious Roots of Alzheimer's Buried Deep in the Past? - Academia.edu, accessed March 23, 2026, https://www.academia.edu/31607911/Are_the_Infectious_Roots_of_Alzheimers_Bu ried_Deep_in_the_Past

20. Cataldo AM, Hamilton DJ, Barnett JL, Paskevich PA, Nixon RA. Properties of the endosomal-lysosomal system in the human central nervous system: disturbances mark most neurons in populations at risk to degenerate in Alzheimer's disease. J Neurosci 1996;16(1):186-99. DOI 10.1523/JNEUROSCI.16-01-00186.1996.

21. Nixon RA, Cataldo AM, Mathews PM. The endosomal-lysosomal system of neurons in Alzheimer's disease pathogenesis: a review. Neurochem Res 2000;25(9-10):1161-72. DOI 10.1023/a:1007675508413.

22. TaubCONNECT Research Perspectives, accessed March 23, 2026, https://columbianeuroresearch.org/taub/res-taub-connect-4-2018.html

23. Linking endo-lysosomal pH, sterol, and trafficking to neurodegenerative disease | FEMS Yeast Research | Oxford Academic, accessed March 23, 2026, https://academic.oup.com/femsyr/article/doi/

    Find this paper

24. Szabo MP, Mishra S, Knupp A, Young JE. The role of Alzheimer's disease risk genes in endolysosomal pathways. Neurobiol Dis 2022;162:105576. DOI 10.1016/j.nbd.2021.105576.

25. Chu J, Praticò D. The retromer complex system in a transgenic mouse model of AD: influence of age. Neurobiology of Aging 2017;52:32-38. DOI 10.1016/j.neurobiolaging.2016.12.025.

26. Lewandowski NM, Small SA. Brain microarray: finding needles in molecular haystacks. J Neurosci 2005;25(45):10341-6. DOI 10.1523/JNEUROSCI.4006-05.2005.

27. Lewandowski NM, Small SA. Brain microarray: finding needles in molecular haystacks. J Neurosci 2005;25(45):10341-6. DOI 10.1523/JNEUROSCI.4006-05.2005.

28. Small SA. Retromer sorting: a pathogenic pathway in late-onset Alzheimer disease. Arch Neurol 2008;65(3):323-8. DOI 10.1001/archneurol.2007.64.

29. Small SA. Isolating pathogenic mechanisms embedded within the hippocampal circuit through regional vulnerability. Neuron 2014;84(1):32-39. DOI 10.1016/j.neuron.2014.08.030.

30. Reilly JF, Games D, Rydel RE, Freedman S, Schenk D, Young WG, et al.. Amyloid deposition in the hippocampus and entorhinal cortex: Quantitative analysis of a transgenic mouse model. Proceedings of the National Academy of Sciences 2003;100(8):4837-4842. DOI 10.1073/pnas.0330745100.

31. Lewandowski NM, Small SA. Brain Microarray: Finding Needles in Molecular Haystacks. The Journal of Neuroscience 2005;25(45):10341-10346. DOI 10.1523/jneurosci.4006-05.2005.

32. Retromer in Synaptic Function and Pathology - Frontiers, accessed March 23, 2026, https://www.frontiersin.org/journals/synaptic-neuroscience/articles/ 2018.00037/full

33. Mutations in SORL1 and MTHFDL1 possibly contribute to the development of

34. Li Y, Laws SM, Miles LA, Wiley JS, Huang X, Masters CL, et al.. Genomics of Alzheimer's disease implicates the innate and adaptive immune systems. Cell Mol Life Sci 2021;78(23):7397-7426. DOI 10.1007/s00018-021-03986-5.

35. Retromer binds to the SORLA dimer. (A) Schematic depiction showing... - ResearchGate, accessed March 23, 2026, https://www.researchgate.net/figure/Retromer-binds-to-the-SORLA-dimer-A-Sc hematic-depiction-showing-SORLA-proteins-with_fig2_367252171 38. (PDF) Targeting Calpain-2 for Alzheimer's Disease Treatment - ResearchGate, accessed March 23, 2026, https://www.researchgate.net/publication/369902604_Targeting_Calpain-2_for_Al zheimer's_Disease_Treatment 39. (PDF) APOE4/4 is linked to damaging lipid droplets in Alzheimer's microglia - ResearchGate, accessed March 23, 2026, https://www.researchgate.net/publication/372634710_APOE44_is_linked_to_dam aging_lipid_droplets_in_Alzheimer's_microglia

36. Small SA, Simoes-Spassov S, Mayeux R, Petsko GA. Endosomal Traffic Jams Represent a Pathogenic Hub and Therapeutic Target in Alzheimer's Disease. Trends Neurosci 2017;40(10):592-602.2017.08.003.

    Find this paper

37. Qureshi YH, Berman DE, Marsh SE, Klein RL, Patel VM, Simoes S, et al.. The neuronal retromer can regulate both neuronal and microglial phenotypes of Alzheimer's disease. Cell Rep 2022;38(3):110262.2021.110262.

    Find this paper

38. Endosomal trafficking could be a target for Alzheimer's therapies - Drug Target Review, accessed March 23, 2026, https://www.drugtargetreview.com/news/77069/endosomal-trafficking-could-bea-target-for-alzheimers-therapies/

39. Alzheimer's Disease: Tau Pathology and Dysfunction of Endocytosis - Frontiers, accessed March 23, 2026, https://www.frontiersin.org/journals/molecular-neuroscience/articles/ ol.2020.583755/full

40. Simoes S, Neufeld JL, Triana-Baltzer G, Moughadam S, Chen EI, Kothiya M, et al.. Tau and other proteins found in Alzheimer's disease spinal fluid are linked to retromer-mediated endosomal traffic in mice and humans. Sci Transl Med 2020;12(571). DOI 10.1126/scitranslmed.aba6334.

41. Biomarkers of Errant Endosome Spotted in Cerebrospinal Fluid - Alzforum, accessed March 23, 2026, https://www.alzforum.org/news/research-news/biomarkers-errant-endosome-sp otted-cerebrospinal-fluid

42. Shaw G. Study Offers New Insights Into Regional Vulnerability in Alzheimer's Disease. Neurology Today 2025;25(21):12-13. DOI 10.1097/01.wnt.0001172344.73021.31.

43. Lateral Entorhinal Cortex Dysfunction in Alzheimer's disease Mice Abstract Introduction - bioRxiv, accessed March 23, 2026, DOI 10.1101/2024.04.15.589589">https://www.biorxiv.org/content/10.1101/2024.04.15.589589

44. Selective Vulnerability of Neurons in Layer II of the Entorhinal Cortex during Aging

45. Simoes S, Guo J, Buitrago L, Qureshi YH, Feng X, Kothiya M, et al.. Alzheimer's vulnerable brain region relies on a distinct retromer core dedicated to endosomal recycling. Cell Rep 2021;37(13):110182.2021.110182.

    Find this paper

46. Curtis ME, Smith T, Blass BE, Praticò D. Dysfunction of the retromer complex system contributes to amyloid and tau pathology in a stem cell model of Down syndrome. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2022;8(1). DOI 10.1002/trc2.12334.

47. Montagnese M, Ebneabbasi A, García-San-Martín N, Pecci-Terroba C, Romero-García R, Morgan SE, et al.. Structural similarity networks reveal brain vulnerability in dementia. Alzheimers Dement 2025;21(12):e70973. DOI 10.1002/alz.70973.

48. Structural Similarity Networks Reveal Brain Vulnerability in Dementia - medRxiv, accessed March 23, 2026, https://www.medrxiv.org/content/

49. New Approach to Alzheimer's Treatment | Columbia University Irving..., accessed March 23, 2026, https://www.cuimc.columbia.edu/news/new-approach-alzheimers-treatment

50. Retromer Therapeutics 2026 Company Profile: Valuation, Funding & Investors | PitchBook, accessed March 23, 2026, https://pitchbook.com/profiles/company/503405-29

51. Young JE, Fong LK, Frankowski H, Petsko GA, Small SA, Goldstein LSB. Stabilizing the Retromer Complex in a Human Stem Cell Model of Alzheimer's Disease Reduces TAU Phosphorylation Independently of Amyloid Precursor Protein. Stem Cell Reports 2018;10(3):1046-1058. DOI 10.1016/j.stemcr.2018.01.031.

52. Pharmacologic Stabilization of Retromer Rescues Endosomal Pathology Induced by Defects in the Alzheimer's gene SORL1 | bioRxiv, accessed March 23, 2026, https://www.biorxiv.org/content/

53. RhoGEF12 regulates endosomal SORL1-retromer and its inhibition is therapeutic in human neuronal models of Alzheimer's disease | bioRxiv, accessed March 23, 2026, DOI 10.64898/2026.03.06.709427">https://www.biorxiv.org/content/10.64898/2026.03.06.709427

54. AAV9-SORL1(Retromer) - Drug Targets, Indications, Patents - Patsnap Synapse, accessed March 23, 2026, https://synapse.patsnap.com/drug/5de5029383a94626b70cb389504e342c

55. Retromer Therapeutics Corp. - Drug pipelines, Patents, Clinical trials - Synapse, accessed March 23, 2026, https://synapse-patsnap-com.libproxy1.nus.edu.sg/organization/e7d7dd58cfcd7e 5445d77ba24e64893c

56. Andersen OM, Qureshi YH, Jensen AMG, Williams A, Young JE, Roy M, et al.. AAV9‐SORL1 gene therapy for Alzheimer’s disease. Alzheimer's & Dementia 2024;20(S6). DOI 10.1002/alz.088971.

57. Qureshi YH, Williams CA, Hajdu I, Kannan S, Govindarajan A, Végh B, et al.. RhoGEF12 regulates endosomal SORL1-retromer and its inhibition is therapeutic in human neuronal models of Alzheimer’s disease. 2026. DOI 10.64898/2026.03.06.709427.

58. Mice and minipigs with compromised expression of the Alzheimer's disease gene SORL1 show cerebral metabolic disturbances on hyperpolarized [1-13C]pyruvate and sodium MRI | Brain Communications | Oxford Academic, accessed March 23, 2026,

https://academic.oup.com/braincomms/article/6/2/fcae114/7638291

64. Arnsten AFT, Datta D, Leslie S, Yang S, Wang M, Nairn AC. Alzheimer’s-like pathology in aging rhesus macaques: Unique opportunity to study the etiology and treatment of Alzheimer’s disease. Proceedings of the National Academy of Sciences 2019;116(52):26230-26238. DOI 10.1073/pnas.1903671116.

65. Limone A, Veneruso I, D'Argenio V, Sarnataro D. Endosomal trafficking and related genetic underpinnings as a hub in Alzheimer's disease. J Cell Physiol 2022;237(10):3803-3815. DOI 10.1002/jcp.30864.

66. Rothwell ES, Carp SB, Bliss-Moreau E. The importance of social behavior in nonhuman primate studies of aging: A mini-review. Neuroscience & Biobehavioral Reviews 2023;154:105422. DOI 10.1016/j.neubiorev.2023.105422.

67. Maninger J, Nowak K, Goberdhan S, O'Donoghue R, Connor-Robson N. Cell type-specific functions of Alzheimer's disease endocytic risk genes. Philosophical Transactions of the Royal Society B: Biological Sciences 2024;379(1899). DOI 10.1098/rstb.2022.0378.

68. Clinical Trials on Alzheimer's Disease (CTAD) 2025 | ALZFORUM, accessed March 23, 2026, https://www.alzforum.org/print-series/3615261